Nucleome Therapeutics
Nucleome is a biotechnology company focused on decoding the regulatory genome to advance the next generation of personalized medicines. Founded in 2019 by experts from the University of Oxford, Nucleome utilizes a proprietary platform integrating laboratory and machine learning technologies to interrogate the genome at a base-pair level. This platform aims to elucidate the mechanistic basis of disease, discover genetically validated drug targets, and stratify patients for improved treatment outcomes. The company initially focuses on inflammatory conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease, and multiple sclerosis. Nucleome collaborates with pharmaceutical companies to identify targets and patient subgroups, and is backed by prominent investors including M Ventures, Johnson & Johnson Innovation-JJDC, Inc., and Pfizer Ventures.
Nucleome Therapeutics
Nucleome is a biotechnology company focused on decoding the regulatory genome to advance the next generation of personalized medicines. Founded in 2019 by experts from the University of Oxford, Nucleome utilizes a proprietary platform integrating laboratory and machine learning technologies to interrogate the genome at a base-pair level. This platform aims to elucidate the mechanistic basis of disease, discover genetically validated drug targets, and stratify patients for improved treatment outcomes. The company initially focuses on inflammatory conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease, and multiple sclerosis. Nucleome collaborates with pharmaceutical companies to identify targets and patient subgroups, and is backed by prominent investors including M Ventures, Johnson & Johnson Innovation-JJDC, Inc., and Pfizer Ventures.